Drugs / CART-EGFR-IL13Ra2 Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06973096 | Jul 2025 → Jul 2042 expected | glioblastoma | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 1 | NCT05168423 | Feb 2023 → Dec 2039 expected | glioblastoma | University of Pennsylvania | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-EGFR-IL13Ra2 Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05168423 ↗ |
| Known as | CART-EGFR-IL13Rα2 cells | “or CART-EGFR-IL13Rα2 cells, in patients with EGFR-amplified rGBM” PMID 40451950 ↗ Jun 2025 |
| Modality | Cell therapy | “bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor (EGFR) epitope 806 and interleukin-13 receptor alpha 2 (IL-13Rα2)” PMID 40451950 ↗ Jun 2025 |
| Route | Intrathecal | “via intrathecal administration” NCT05168423 ↗ |
| Target | EGFR | “targeting epidermal growth factor receptor (EGFR) epitope 806” PMID 40451950 ↗ Jun 2025 |